Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome
Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results. Read more about this abstract on the AAN we bsite . Show…
Read the full articleYou might also wanna read
Phase I CARLYSLE study: CAR T-cell therapy obe-cel shows favorable safety and clinical benefit in severe refractory lupus
Objectives To report initial safety, efficacy, pharmacokinetics (PK) and biomarker analyses in patients with srSLE, treated with obe-cel in
lupus.bmj.com·1mo ago
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP de
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells
Deep phenotyping reveals that CD19-CAR T cell therapy in SSc patients shows potential in reversing skin fibrosis. Explore how molecular insi
A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials
Conditions : Participants Treated With Senza5 Interventions : Biological: Senza5 CART5 Sponsors : Vittoria Biotherapeutics Not yet recruitin
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
Conditions : CLDN18.2 Positive Solid Tumors Interventions : Biological: SUV2208A cell injection; Biological: SUV2208A; Biological: SUV2208A
A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Conditions : T-Cell Acute Lymphoblastic Leukemia; T-Lymphoblastic Lymphoma; Relapsed/Refractory Hematologic Malignancies Interventions : Bio
Comments
Sign in to join the conversation.
No comments yet. Be the first.